Madrigal Pharmaceuticals, Inc. MDGL Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s long-term debt?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported long-term debt of $340.33M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s long-term debt increased by 188.4% year-over-year, from $118.01M to $340.33M.
- What does long-term debt mean?
- Debt that is not due for repayment within the next year.
- How do you interpret long-term debt?
- Increased debt levels raise interest expense and financial risk, though they may be necessary to fund long-term growth or clinical trials.
- How does long-term debt compare across companies?
- Highly dependent on the company's access to capital markets and current interest rate environments.